India’s pharmaceutical exports are set to double to reach US$ 65 billion by 2030, driven by strategic moves into complex generics, advanced therapies, and global expansion, reveals a recent report by Rubix Data Sciences. Despite US tariff threats and heavy reliance on China for bulk drugs, Indian pharma is improving...
U.S. President Donald Trump has announced a 50% tariff on copper imports and proposed raising pharmaceutical tariffs up to 200% within a year. These measures are part of a broader strategy targeting key sectors like semiconductors, critical minerals, and medicines. The tariffs will take effect from August 1, 2025, with...
Dr. Gunjan Kishor Sharma, a physician and passionate health tech innovator, is the driving force behind MeshApp.ai—a platform redefining communication and collaboration in the pharmaceutical and healthcare ecosystem. With firsthand experience of the fragmented interactions between pharma companies, medical reps, and doctors, Dr. Sharma founded MeshApp to bridge this gap...
India’s pharmaceutical industry, valued at US$ 55 billion in FY 2023-24, is rapidly emerging as a global healthcare powerhouse. With projections to reach US$ 130 billion by 2030 and an aspirational US$ 450 billion by 2047, the sector is set to nearly double its global market share to 5%. Already...
U.S. President Trump’s “Most Favoured Nation” (MFN) pricing policy seeks to lower prescription drug costs by ensuring the U.S. pays no more than the lowest price worldwide. This could pressure countries like India, a major producer of affordable generics, to raise drug prices — potentially undermining the global competitiveness of...
The Department of Pharmaceuticals has called for Expressions of Interest (EoIs) from interested entities (including proprietary firm or partnership firm or limited liability partnership, startups or a company /Group of companies registered in India) for project funding under the PRIP scheme, which is designed to position India as a global...
India’s pharma exports are expected to double to US$ 65 billion by 2030 and reach US$ 350 billion in value terms by 2047, moving to the top five position globally by diversifying its product basket, reveals a new report by Bain & Company. The report highlights the need for innovation,...
India’s CDMO market is projected to double from US$ 7 billion to US$ 14 billion by 2028, driven by strong API and generic drug manufacturing capabilities, along with cost advantages over China. India’s Contract Development and Manufacturing Organization (CDMO) market is on track for substantial expansion, projected to double from...
The Indian pharmaceutical industry, a global leader in high-quality, low-cost drug production, commands over 20% of global generics supply and addresses 60% of worldwide vaccine demand. Crucial to India’s economic growth and employment, the industry benefits from government initiatives like the Production Linked Incentive (PLI) scheme, which supports production, boosts...
The Chinese OTC drugs market presents a lucrative billion-dollar opportunity for Indian pharmaceutical companies. In 2019, China’s National Medical Products Administration launched a trial program to introduce over-the-counter (OTC) products through bonded warehouses in CBEC (Cross-Border eCommerce) Free Trade Zones. This initiative, now expanded to multiple regions, enables the sale...
India Business & Trade is a thought leadership initiative of the Trade Promotion Council of India, a premier trade promotion body recognised by the Department of Commerce, Government of India.
India Business & Trade
M-62, Saket, New Delhi-110064, India
Stay ahead in the dynamic world of trade and commerce with India Business & Trade’s weekly newsletter.
Copyright © 2026 India Business & Trade. All Rights Reserved
